Yazar "Bahadir, Veysi" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Can Paricalcitol Increase the Effectiveness of N-Acetylcysteine in Contrast Induced Acute Kidney Prophylaxis in Rats? A Biochemical and Histopathological Study(Soc Chilena Anatomia, 2022) Yildirim, Yasar; Bahadir, Veysi; Aydin, Emre; Aydin, Fatma Yilmaz; Yilmaz, Zulfukar; Ketani, Aydin; Kaplan, Ibrahim& nbsp;N-Acetylcysteine (NAC) is used for contrast induced acut kidney injury (CI-AKI) prophylaxis because of its antioxidant effects. Paricalcitol, which has reno-protective effects, is likely to provide a more effective prophylaxis when added to NAC treatment. The study was designed based on this hypothesis. The study was organised to include 4 groups each consisting of 7 rats. Group 1 was the control group, and Group 2 included rats with CI-AKI. Rats in Group 3 were administered NAC at a dose of 100 mg/kg via oral gavage once a day for 5 days. Rats in group 4 were administered paricalcitol at a dose of 0.4 mcg/kg once a day for 5 days in addition to NAC. CI-AKI was induced after the treatments in both groups. The study was terminated on the sixth day. Samples were collected from the rats & rsquo; sera and kidney tissues to study oxidant and antioxidant parameters; kidney function tests were also studied. There were significant differences between the contrast nephropathy group (Group 2) and NAC and NAC+paricalcitol groups with respect to serum urea and creatinine levels. When the same groups were compared regarding oxidant (TOS-MDA) and antioxidant (TAC-Paraoxonase) parameters, we observed that the oxidant parameters increased in serum and kidney tissue samples with NAC use, and that effect was strengthened by the addition of paricalcitol to NAC treatment. However, despite increased antioxidant effectiveness, we observed no decrease in urea and creatinine levels when paricalcitol was added for CI-AKI in rats. There was no significant difference between Group 3 and Group 4. Paricalcitol provides a more potent antioxidant effect in both serum and kidney tissue samples when added to NAC treatment in rats with CI-AKI. Despite increased antioxidant parameters, however, paricalcitol does not provide a significant decrease in urea and creatinine levels.Öğe PRETREATMENT WITH PARICALCITOL ATTENUATES OXIDATIVE STRESS IN RENAL ISCHEMIA REPERFUSION INDUCED NEPHROPATY IN RATS(Oxford Univ Press, 2016) Yildirim, Yasar; Yilmaz, Zulfukar; Kadiroglu, Ali K.; Kara, Ali V.; Bahadir, Veysi; Aydin, Emre; Aydin, Fatma Y.[Abstract Not Available]Öğe Pretreatment with Paricalcitol Attenuates Oxidative Stress in Renal lschemia Reperfusion-Induced Nephropathy in Rats(Sci Printers & Publ Inc, 2020) Aydin, Fatma Yilmaz; Yilmaz, Zulfukar; Yildirim, Yasar; Aydin, Emre; Ketani, Aydin; Bahadir, Veysi; Kaplan, IbrahimOBJECTIVE: To investigate whether paricalcitol could ameliorate kidney injury due to ischemia reperfusion (I/R) in an experimental study. STUDY DESIGN: Rats were divided into 4 groups: control, paricalcitol, I/R, and paricalcitol +I/R, each containing 7 animals. Intraperitoneal 0.3 mu g/kg paricalcitol was administered to rats once a day for 5 consecutive days in the paricalcitol and paricalcitol+1/R groups. After right nephrectomy, rats were exposed to ischemia/ reperfusion on day 6 in the paricalcitol+1/R and I/R groups. Oxidant and antioxidant parameters, kidney function tests, and histology were investigated. RESULTS: Serum urea and creatinine levels exhibited a significant decrease in rats treated with paricalcitol before I/R as compared to rats exposed just to I/R. In a comparison of the paricalcitol +1/R group with the I/R group, serum total oxidant status (TOS) levels decreased significantly; serum total antioxidant capacity (TAC) and nitric oxide levels, however, increased significantly with paricalcitol administration. Malondialdehyde and TOS levels of kidney tissue were significantly lower, whereas TAC and paraoxonase levels were higher in the paricalcitol +I/R group than in the I/R group. Renal tissue injury scores were found to be significantly higher in the I/R group than in the paricalcitol+ I/R group. CONCLUSION: Pretreatment with paricalcitol was detected to be renoprotective by decreasing renal injury related with renal I/R, which was assessed by improved renal function and histopathologii.Öğe The protective effects of paricalcitol on renal ischemia reperfusion induced lung injury(European Respiratory Soc Journals Ltd, 2018) Yilmaz, Sureyya; Yilmaz, Zulfukar; Kadiroglu, Ali Kemal; Bahadir, Veysi; Kaplan, Ibrahim; Ketani, Aydin; Yilmaz, Engin Deniz[Abstract Not Available]Öğe Protective Effects of Paricalcitol on Renal Ischemia/Reperfusion-Induced Lung Injury(Sci Printers & Publ Inc, 2021) Yilmaz, Sureyya; Yildirim, Yasar; Kadiroglu, Ali Kemal; Bahadir, Veysi; Aydin, Emre; Aydin, Fatma Yilmaz; Ketani, AydinOBJECTIVE: Acute kidney injury (AKI) is a common and important clinical challenge, and renal ischemia/reperfusion (I/R) injury is the major reason of AKI. Renal I/R can lead to lung injury, which is associated with increased mortality. This study was designed to evaluate whether paricalcitol may protect against lung injury following renal I/R injury via its antioxidant properties. STUDY DESIGN: Rats (n=7 per group) were divided into 4 groups: control, paricalcitol, I/R, and paricalcitol + I/R. Rats received daily intraperitoneal injection of paricalcitol (0.3 mu g/kg) for 5 days in the paricalcitol and paricalcitol + I/R groups. On day 6, rats were subjected to I/R injury (60 minutes of left renal artery occlusion followed by 60 minutes of reperfusion) after right nephrectomy. Renal function tests, oxidant and anti-oxidant parameters, and lung histology of both groups were examined. RESULTS: Pretreatment of rats with paricalcitol in the paricalcitol + I/R group significantly decreased serum urea and creatinine levels as compared with the I/R group (p < 0.05). Malondialdehyde (MDA) and total oxidant status (TOS) levels were significantly increased in serum and lung tissue of the I/R group as compared with the control and paricalcitol groups (p < 0.05). Rats treated with paricalcitol prior to I/R injury exhibited significant reduction in terms of serum and lung tissue TOS and MDA levels and significant increase in terms of serum and lung tissue nitric oxide and total antioxidant capacity levels (p < 0.05). The lung histopathological scores were significantly higher in the I/R group as compared with the paricalcitol + I/R group (p < 0.05). CONCLUSION: Paricalcitol may ameliorate renal I/Rinduced lung injury by attenuating oxidative stress.
